Xeljanz XR 11 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F9R1D
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,082
Award facts
- Contract value 100% obligated
- $12,082.03 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $12,082.03 on January 20, 2026, for the supply of XELJANZ XR 11 mg tablets (30-count unit of use packaging). This firm fixed-price delivery order, which is not designated as a set-aside contract, was competitively awarded by the Defense Logistics Agency (DLA) and is scheduled for completion by January 21, 2026. The contract represents a task order placed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc. (formerly operating as AmerisourceBergen), which holds the parent Indefinite Delivery Contract with the DLA. The DLA's Medical Supply Chain procures critical pharmaceutical commodities including specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military treatment facilities and other federal healthcare systems. This particular delivery order for XELJANZ XR, an immunosuppressant medication used in treating inflammatory conditions, demonstrates the company's role in providing specialized therapeutic medications to Defense Health Agency customers and other government healthcare institutions.
Quick answers
Who was awarded contract SPE2DR26F9R1D?
SPE2DR26F9R1D was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26F9R1D worth?
The government has obligated $12,082 on SPE2DR26F9R1D.
Is contract SPE2DR26F9R1D an order under another contract?
Yes. SPE2DR26F9R1D is a delivery order under SPE2DR25D3020, an indefinite delivery contract.
Was contract SPE2DR26F9R1D competed?
The extent of competition for SPE2DR26F9R1D was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award